Quarterly out Monday see if it's same cut and paste. To be honest any hint of production the .003 is a bargain buy.. Would be a significant rerate? 1-2m ebitda+ P.a imo?
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
